The World Health Organization (WHO) has issued a renewed call for member states to adopt standardized pricing transparency frameworks for pharmaceutical products, citing persistent access barriers in low- and middle-income countries.
The resolution, supported by 72 countries, recommends mandatory disclosure of net prices, R&D costs, and government subsidy data.